Photo of Jeffrey Tyner, Ph.D.

Jeffrey Tyner Ph.D.

  • (503) 346-0603
    • Associate Professor of Medicine School of Medicine
    • Cell and Developmental Biology Graduate Program School of Medicine
    • Cancer Biology Graduate Program School of Medicine

Publications

  • "Kinase Inhibitor Screening in Myeloid Malignancies." Hematology/Oncology Clinics of North America In: , Vol. 31, No. 4, 01.08.2017, p. 693-704.
  • "Identification of targeted therapies for rare adult mature T-cell leukemia using functional ex vivo screening of primary patient samples." American Journal of Hematology  In: , Vol. 92, No. 5, 01.05.2017, p. E64-E66.
  • "Identification of Interleukin-1 by Functional Screening as a Key Mediator of Cellular Expansion and Disease Progression in Acute Myeloid Leukemia." Cell Reports  In: , Vol. 18, No. 13, 28.03.2017, p. 3204-3218.
  • "UNC2025, a MERTK small-molecule inhibitor, is therapeutically effective alone and in combination with methotrexate in leukemia models." Clinical Cancer Research In: , Vol. 23, No. 6, 15.03.2017, p. 1481-1492.
  • "Genomics of chronic neutrophilic leukemia." Blood In: , Vol. 129, No. 6, 09.02.2017, p. 715-722.
  • "CPX-351 exhibits potent and direct ex vivo cytotoxicity against AML blasts with enhanced efficacy for cells harboring the FLT3-ITD mutation." Leukemia Research In: , Vol. 53, 01.02.2017, p. 39-49.
  • "Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors." Oncotarget  In: , Vol. 8, No. 14, 2017, p. 22606-22615.
  • "Small molecule inhibitor screening identifified HSP90 inhibitor 17-AAG as potential therapeutic agent for gallbladder cancer." Oncotarget In: , Vol. 8, No. 16, 2017, p. 26169-26184.
  • "FGF2 from marrow microenvironment promotes resistance to FLT3 inhibitors in acute myeloid leukemia." Cancer Research In: , Vol. 76, No. 22, 15.11.2016, p. 6471-6482.
  • "Discovery and functional characterization of a germline, CSF2RB-activating mutation in leukemia." Leukemia In: , Vol. 30, No. 9, 01.09.2016, p. 1950-1953.
  • "Targeting BCL-2 and ABL/LYN in Philadelphia chromosome-positive acute lymphoblastic leukemia." Science Translational Medicine In: , Vol. 8, No. 354, 354ra114, 31.08.2016.
  • "Ultrasensitive proteomic quantitation of cellular signaling by digitized nanoparticle-protein counting." Scientific Reports In: , Vol. 6, 28163, 20.06.2016.
  • "JAKed up phenotype of CEBPA-mutant AML." Blood In: , Vol. 127, No. 24, 16.06.2016, p. 2946-2947.
  • "Targeting super-enhancer-associated oncogenes in oesophageal squamous cell carcinoma." Gut  In: , 10.05.2016.
  • "Clonality of neutrophilia associated with plasma cell neoplasms : Report of a SETBP1 mutation and analysis of a single institution series." Leukemia and Lymphoma In: , Vol. 57, No. 4, 02.04.2016, p. 927-934.
  • "Alterations in acute myeloid leukaemia bone marrow stromal cell exosome content coincide with gains in tyrosine kinase inhibitor resistance." British Journal of Haematology  In: , Vol. 172, No. 6, 01.03.2016, p. 983-986.
  • "The colony-Stimulating factor 3 receptor T640N mutation is oncogenic, sensitive toJAKInhibition, and mimics T618i." Clinical Cancer Research In: , Vol. 22, No. 3, 01.02.2016, p. 757-764.
  • "Mutant calreticulin-expressing cells induce monocyte hyperreactivity through a paracrine mechanism." American Journal of Hematology  In: , Vol. 91, No. 2, 01.02.2016, p. 211-219.
  • "Identification and characterization of tyrosine kinase nonreceptor 2 mutations in leukemia through integration of kinase inhibitor screening and genomic analysis." Cancer Research In: , Vol. 76, No. 1, 01.01.2016, p. 127-138.
  • "RNAi screening of leukemia cells using electroporation."  Methods in Molecular Biology. Vol. 1470 Humana Press Inc., 2016. p. 85-94 (Methods in Molecular Biology; Vol. 1470).
  • "Combined targeting of SET and tyrosine kinases provides an effective therapeutic approach in human T-cell acute lymphoblastic leukemia." Oncotarget  In: , Vol. 7, No. 51, 2016, p. 84214-84227.
  • "Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent." Journal of Hematology and Oncology  In: , Vol. 9, No. 1, 31, 2016.
  • "Age-related mutations and chronic myelomonocytic leukemia." Leukemia In: , 09.12.2015.
  • "What's different about atypical CML and chronic neutrophilic leukemia?" Hematology In: , Vol. 2015, No. 1, 05.12.2015, p. 264-271.
  • "Functional RNAi screen targeting cytokine and growth factor receptors reveals oncorequisite role for interleukin-2 gamma receptor in JAK3-mutation-positive leukemia." Oncogene In: , Vol. 34, No. 23, 04.06.2015, p. 2991-2999.
  • "Therapeutically targetable ALK mutations in leukemia." Cancer Research In: , Vol. 75, No. 11, 01.06.2015, p. 2146-2150.
  • "The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development." Nature Cell Biology  In: , Vol. 17, No. 5, 05.05.2015, p. 665-677.
  • "Integrated analysis of CRLF2 signaling in acute lymphoblastic leukemia identifies Polo-like kinase 1 as a potential therapeutic target." Leukemia and Lymphoma  In: , Vol. 56, No. 5, 01.05.2015, p. 1524-1527.
  • "YM155 potently kills acute lymphoblastic leukemia cells through activation of the DNA damage pathway." Journal of Hematology and Oncology In: , Vol. 8, No. 1, 39, 22.04.2015.
  • "Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer." Molecular Oncology  In: , Vol. 9, No. 4, 01.04.2015, p. 889-905.

Additional information

Edit profile